Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus acidophilus L-92 and Improved Atopic Dermatitis Severity

Research synthesisModerate evidenceModerate effect4 studies · 4 beneficial · 0 neutral · 0 harmful

Across 4 studies, all reported beneficial moderate-sized effects of Lactobacillus acidophilus L-92 on improving atopic dermatitis severity. Three of four studies found statistically significant reductions in SCORAD or similar clinical severity scores. Most evidence comes from small clinical trials in children and adults, with one study using a dose of 20 mg L-92/day.

  • Effective dose range: 20 mg L-92/day
  • Studied populations: children with atopic dermatitis and food allergy; adults with atopic dermatitis

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Two studies did not report dose, limiting dose-to-effect conclusions. One study used heat-killed L-92, which may differ mechanistically from live probiotic forms.

Generated Jun 11, 2026
Doses used in studies
  • CFU/day: 1 (median 1, IQR 1–1) — 1 study
  • mg/day: 20 (median 20, IQR 20–20) — 1 study
Safety in these studies
4 of 4 papers
Back to top